The Critical Path for Alzheimer’s Disease (CPAD) consortium’s primary objective is to promote, support, and manage pre‐competitive data sharing from Alzheimer disease (AD) clinical trials to allow quantification of Alzheimer’s Disease progression across the AD continuum. A quantitative understanding of disease dynamics will drive scientific discovery provided by aggregated and standardized primary clinical trial data. This will provide solutions to optimize the design of clinical trials of AD drugs intended for regulatory review in support of marketing approval. CPAD is a nonprofit, pre‐competitive consortium (https://c‐path.org/programs/cpad/) of the Critical Path Institute (C‐Path) and convenes diverse stakeholders from academia, advocacy groups, industry, and regulators.